PHL-LOXAPINE 2.5 MG
LOXAPINE (LOXAPINE SUCCINATE) : 2.5 MG · DIN 02255448 · PHARMEL INC
Health Canada status: CANCELLED POST MARKET
What is PHL-LOXAPINE?
PHL-LOXAPINE 2.5 MG contains LOXAPINE (LOXAPINE SUCCINATE) : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02255448, held by PHARMEL INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 25-Oct-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PHL-LOXAPINE used for?
Management of the manifestations of schizophrenia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02255448 |
|---|---|
| Brand name | PHL-LOXAPINE |
| Generic / active ingredient | LOXAPINE (LOXAPINE SUCCINATE) : 2.5 MG |
| Manufacturer | PHARMEL INC |
| Strength | 2.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AH01 LOXAPINE |
| AHFS class | 28:16.08.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 25-Oct-2016 |
| Original market date | 2004-07-22 00:00:00 |
How is it administered?
Initial: 10 mg twice daily. Usual range: 60-100 mg daily in divided doses. Max: 250 mg/day. Maintenance: 20-60 mg daily. Oral concentrate should be mixed with juice.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature (15°C to 30°C) in tightly closed containers.
How is it supplied?
Tablets: Bottles of 100 and 500. Oral Concentrate: 100 mL glass bottles with calibrated syringes.
Contraindications
Comatose or severe drug-induced depressed states; known hypersensitivity to the drug; circulatory collapse.
Warnings and precautions
Tardive Dyskinesia, Neuroleptic Malignant Syndrome (NMS), potential to impair mental/physical abilities, lowers convulsive threshold, caution in cardiovascular disease and glaucoma.
What can be used instead?
Other Canadian products sharing ATC code N05AH01 LOXAPINE. 4 of 51 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| LOXAPAC IM | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02169991 |
| XYLAC | 10 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02230838 |
| XYLAC | 2.5 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02242868 |
| XYLAC | 25 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02230839 |
| APO-LOXAPINE | 10 MG | TABLET | APOTEX INC | APPROVED | DIN 02237652 |
| APO-LOXAPINE | 25 MG | TABLET | APOTEX INC | APPROVED | DIN 02237653 |
| APO-LOXAPINE | 5 MG | TABLET | APOTEX INC | APPROVED | DIN 02237651 |
| APO-LOXAPINE | 50 MG | TABLET | APOTEX INC | APPROVED | DIN 02237654 |
| DOM-LOXAPINE TABLETS 10MG | 10 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239919 |
| DOM-LOXAPINE TABLETS 25MG | 25 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239920 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.